CoChat

Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease

Maruyama, Masahiro, Higuchi, Makoto, Takaki, Yoshie, Matsuba, Yukio, Tanji, Haruko, Nemoto, Miyako, Tomita, Naoki, Matsui, Toshifumi, Iwata, Nobuhisa, Mizukami, Hiroaki, Muramatsu, Shin‐Ichi, Ozawa, Keiya, Saido, Takaomi C., Arai, Hiroyuki, Sasaki, Hidetada · 2005 · Annals of Neurology
Cited by 97

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Amyloid β peptide (Aβ) has been implicated in Alzheimer's disease (AD) as an initiator of the pathological cascades. Several lines of compelling evidence have supported major roles of Aβ‐degrading enzyme neprilysin in the pathogenesis of sporadic AD. Here, we have shown a substantial reduction of cerebrospinal fluid (CSF) neprilysin activity (CSF‐NEP) in patients with AD‐converted mild cognitive impairment and early AD as compared with age‐matched control subjects. The altered CSF‐NEP likely reflects changes in neuronal neprilysin, since transfer of neprilysin from brain tissue into CSF was demonstrated by injecting neprilysin‐carrying viral vector into the brains of neprilysin‐deficient mice. Interestingly, CSF‐NEP showed an elevation with the progression of AD. Along with a close association of CSF‐NEP with CSF tau proteins, this finding suggests that presynaptically located neprilysin can be released into CSF as a consequence of synaptic disruption. The impact of neuronal damages on CSF‐NEP was further demonstrated by a prominent increase of CSF‐NEP in rats exhibiting kainate‐induced neurodegeneration. Our results unequivocally indicate significance of CSF‐NEP as a biochemical indicator to pursue a pathological process that involves decreased neprilysin activity and Aβ‐induced synaptic toxicity, and the support the potential benefits of neprilysin up‐regulation in ameliorating neuropathology in prodromal and early AD. Ann Neurol 2005;57:832–842

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.20494

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 97

Metadata

Authors
Maruyama, M., Higuchi, M., Takaki, Y., Matsuba, Y., Tanji, H., Nemoto, M., Tomita, N., Matsui, T., Iwata, N., Mizukami, H., Muramatsu, S., Ozawa, K., Saido, T. C., Arai, H., & Sasaki, H.
Venue
Annals of Neurology
Publisher
Wiley
Published
2005-05-31
Volume
57
Issue
6
Pages
832-842
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2142386529
Cited by
97
References
8
FWCI
4.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. https://app.cochat.ai/papers/10.1002/ana.20494
The paper
Maruyama, M., Higuchi, M., Takaki, Y., Matsuba, Y., Tanji, H., Nemoto, M., Tomita, N., Matsui, T., Iwata, N., Mizukami, H., Muramatsu, S., Ozawa, K., Saido, T. C., Arai, H., & Sasaki, H. (2005). Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Annals of Neurology. https://doi.org/10.1002/ana.20494

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.